India’s Pharma Billionaire Eyes Crown of World’s Top Insulin Supplier (opens original article in a new tab)

Biocon Ltd. is expanding its insulin production to become the world's top supplier as major pharmaceutical companies shift focus to other diabetes and weight-loss drugs.

• Biocon Ltd. aims to become the world's top insulin supplier by increasing production and capturing growing demand.
• Biocon is the third-largest insulin supplier by volume globally and is investing in production capacity expansion.
• Big Pharma is shifting focus to next-generation diabetes and weight-loss drugs, creating opportunities for Biocon in the insulin market.
• Biocon is targeting select markets for generic GLP-1s, avoiding the crowded Indian market.